{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T08:16:07Z","timestamp":1788336967316,"version":"build-2803163510"},"reference-count":77,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.ijantimicag.2023.106946","type":"journal-article","created":{"date-parts":[[2023,8,3]],"date-time":"2023-08-03T22:54:37Z","timestamp":1691103277000},"page":"106946","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Efficacy and safety of vancomycin for the treatment of Staphylococcus aureus bacteraemia: a systematic review and meta-analysis"],"prefix":"10.1016","volume":"62","author":[{"given":"Guanxuanzi","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianli","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6687-9984","authenticated-orcid":false,"given":"Yun","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2023.106946_bib0001","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/d41586-018-07414-w","article-title":"A bacterium\u2019s enemy isn\u2019t your friend","volume":"563","author":"Gilmore","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.ijantimicag.2023.106946_bib0002","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJM199808203390806","article-title":"Staphylococcus aureus infections","volume":"339","author":"Lowy","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2023.106946_bib0003","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1128\/CMR.00134-14","article-title":"Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management","volume":"28","author":"Tong","year":"2015","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.ijantimicag.2023.106946_bib0004","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1001\/jama.2014.9743","article-title":"Clinical management of staphylococcus aureus bacteremia: a review","volume":"312","author":"Holland","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.ijantimicag.2023.106946_bib0005","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1128\/CMR.05022-11","article-title":"IB Predictors of mortality in Staphylococcus aureus bacteremia","volume":"25","author":"van Hal","year":"2012","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.ijantimicag.2023.106946_bib0006","doi-asserted-by":"crossref","first-page":"214","DOI":"10.15585\/mmwr.mm6809e1","article-title":"Vital signs: epidemiology and recent trends in methicillin-resistant and in methicillin-susceptible Staphylococcus aureus bloodstream infections\u2014United States","volume":"68","author":"Kourtis","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.ijantimicag.2023.106946_bib0007","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1086\/345476","article-title":"Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis","volume":"36","author":"Cosgrove","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106946_bib0008","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.jinf.2013.10.015","article-title":"Staphylococcus aureus bloodstream infection: a pooled analysis of five prospective, observational studies","volume":"68","author":"Kaasch","year":"2014","journal-title":"J Infect"},{"key":"10.1016\/j.ijantimicag.2023.106946_bib0009","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.chom.2016.05.023","article-title":"Dual-track clearance of circulating bacteria balances rapid restoration of blood sterility with induction of adaptive immunity","volume":"20","author":"Broadley","year":"2016","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.ijantimicag.2023.106946_bib0010","first-page":"e72","article-title":"2020 ACC\/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"143","author":"Otto","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.ijantimicag.2023.106946_bib0011","doi-asserted-by":"crossref","first-page":"dlaa114","DOI":"10.1093\/jacamr\/dlaa114","article-title":"Treatment of methicillin-resistant Staphylococcus aureus (MRSA): updated guidelines from the UK","volume":"3","author":"Brown","year":"2021","journal-title":"JAC Antimicrob Resist"},{"issue":"625","key":"10.1016\/j.ijantimicag.2023.106946_bib0012","first-page":"e1","article-title":"Diagnosis and treatment of bacteremia and endocarditis due to Staphylococcus aureus: a clinical guideline from the Spanish Society of Clinical Microbiology and Infectious Diseases (SEIMC)","volume":"33","author":"Gudiol","year":"2015","journal-title":"Enfermedades Infecciosas y Microbiologia Clinica"},{"key":"10.1016\/j.ijantimicag.2023.106946_bib0013","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jmii.2013.04.010","article-title":"Guidelines for the treatment of methicillin-resistant Staphylococcus aureus infections in Taiwan","volume":"46","author":"Chen","year":"2013","journal-title":"J Microbiol Immunol Infect = Wei mian yu gan ran za zhi"},{"key":"10.1016\/j.ijantimicag.2023.106946_bib0014","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1093\/cid\/ciq146","article-title":"Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children","volume":"52","author":"Liu","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106946_bib0015","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev.med.50.1.223","article-title":"Coagulase-negative staphylococci: role as pathogens","volume":"50","author":"Huebner","year":"1999","journal-title":"Ann Rev Med"},{"key":"10.1016\/j.ijantimicag.2023.106946_bib0016","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1172\/JCI18535","article-title":"Antimicrobial resistance: the example of Staphylococcus aureus","volume":"111","author":"Lowy","year":"2003","journal-title":"J Clin Investig"},{"key":"10.1016\/j.ijantimicag.2023.106946_bib0017","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1056\/NEJMoa055356","article-title":"Methicillin-resistant S. aureus infections among patients in the emergency department","volume":"355","author":"Moran","year":"2006","journal-title":"N Eng J Med"},{"key":"10.1016\/j.ijantimicag.2023.106946_bib0018","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1128\/AAC.00431-07","article-title":"Fluorescence ratio imaging microscopy shows decreased access of vancomycin to cell wall synthetic sites in vancomycin-resistant Staphylococcus aureus","volume":"51","author":"Pereira","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"issue":"03","key":"10.1016\/j.ijantimicag.2023.106946_bib0019","first-page":"372","volume":"5","year":"2011","journal-title":"Chinese journal of Experimental and Clinical Infectious Desease (Elctronic Edition)"},{"issue":"1","key":"10.1016\/j.ijantimicag.2023.106946_bib0020","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1055\/s-0034-1396906","article-title":"Combination antibiotic treatment of serious methicillin-resistant Staphylococcus aureus infections","volume":"36","author":"Davis","year":"2015","journal-title":"Semin Respir Crit Care Med"},{"issue":"9","key":"10.1016\/j.ijantimicag.2023.106946_bib0021","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1093\/jac\/dkx175","article-title":"Genetic alterations responsible for reduced susceptibility to vancomycin in community-associated MRSA strains of ST72","volume":"72","author":"Baek","year":"2017","journal-title":"J Antimicrob Chemother"},{"issue":"7","key":"10.1016\/j.ijantimicag.2023.106946_bib0022","doi-asserted-by":"crossref","first-page":"809","DOI":"10.2165\/00003495-200969070-00003","article-title":"Ceftaroline: a novel broad-spectrum cephalosporin with activity against meticillin-resistant Staphylococcus aureus","volume":"69","author":"Zhanel","year":"2009","journal-title":"Drugs"},{"issue":"18","key":"10.1016\/j.ijantimicag.2023.106946_bib0023","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1007\/s40265-015-0505-8","article-title":"Lipoglycopeptide Antibacterial Agents in Gram-Positive Infections: A Comparative Review","volume":"75","author":"Van Bambeke","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.ijantimicag.2023.106946_bib0024","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1007\/s40265-021-01576-0","article-title":"Contezolid: first approval","volume":"81","author":"Hoy","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.ijantimicag.2023.106946_bib0025","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/jac\/dki355","article-title":"Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies","volume":"56","author":"Shorr","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106946_bib0026","doi-asserted-by":"crossref","first-page":"839","DOI":"10.5414\/CP202996","article-title":"A comparison of telavancin and vancomycin for treatment of methicillin-resistant Staphylococcus aureus infections: a meta-analysis","volume":"55","author":"Liu","year":"2017","journal-title":"Int J Clin Pharmacol Therapeut"},{"key":"10.1016\/j.ijantimicag.2023.106946_bib0027","article-title":"Daptomycin versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus bloodstream infection with or without endocarditis: a systematic review and meta-analysis","volume":"10","author":"Maraolo","year":"2021","journal-title":"Antibiotics (Basel, Switzerland)"},{"key":"10.1016\/j.ijantimicag.2023.106946_bib0028","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0260539","article-title":"Abdi A Efficacy and safety of novel glycopeptides versus vancomycin for the treatment of gram-positive bacterial infections including methicillin resistant Staphylococcus aureus: a systematic review and meta-analysis","volume":"16","author":"Jame","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.ijantimicag.2023.106946_bib0029","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ijantimicag.2023.106946_bib0030","unstructured":"Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et\u00a0al. The Newcastle\u2013Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. [cited 2022 November 22]; http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.htm."},{"key":"10.1016\/j.ijantimicag.2023.106946_bib0031","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.ijantimicag.2023.106946_bib0032","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-2288-5-13","article-title":"Hozo I Estimating the mean and variance from the median, range, and the size of a sample","volume":"5","author":"Hozo","year":"2005","journal-title":"BMC Medical Research Methodology"},{"key":"10.1016\/j.ijantimicag.2023.106946_bib0033","series-title":"Cochrane Handbook for Systematic Reviews of Interventions","year":"2011"},{"key":"10.1016\/j.ijantimicag.2023.106946_bib0034","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1128\/AAC.35.1.79","article-title":"Failure of treatment with teicoplanin at 6 milligrams\/kilogram\/day in patients with Staphylococcus aureus intravascular infection","volume":"35","author":"Gilbert","year":"1991","journal-title":"Infectious Diseases Consortium of Oregon. Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106946_bib0035","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1128\/AAC.35.3.451","article-title":"Randomized study of vancomycin versus teicoplanin for the treatment of Gram-positive bacterial infections in immunocompromised hosts","volume":"35","author":"Van der Auwera","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106946_bib0036","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1128\/AAC.38.9.2041","article-title":"Effects of teicoplanin and those of vancomycin in initial empirical antibiotic regimen for febrile, neutropenic patients with hematologic malignancies","volume":"38","author":"Menichetti","year":"1994","journal-title":"Gimema Infection Program. Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106946_bib0037","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1093\/infdis\/169.2.350","article-title":"Bodey GP A randomized double-blind trial of vancomycin versus teicoplanin for the treatment of Gram-positive bacteremia in patients with cancer","volume":"169","author":"Rolston","year":"1994","journal-title":"J Infect Dis"},{"issue":"199","key":"10.1016\/j.ijantimicag.2023.106946_bib0038","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s100960050258","article-title":"Prospective, randomized dose-ranging open phase II pilot study of quinupristin\/dalfopristin versus vancomycin in the treatment of catheter-related staphylococcal bacteremia","volume":"18","author":"Raad","year":"1999","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106946_bib0039","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1086\/340353","article-title":"Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections","volume":"34","author":"Stevens","year":"2002","journal-title":"Clin Infect Dis"},{"issue":"9 Suppl","key":"10.1016\/j.ijantimicag.2023.106946_bib0040","doi-asserted-by":"crossref","first-page":"S164","DOI":"10.1097\/01.inf.0000086956.45566.55","article-title":"Linezolid for the treatment of children with bacteremia or nosocomial pneumonia caused by resistant Gram-positive bacterial pathogens","volume":"22","author":"Jantausch","year":"2003","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.ijantimicag.2023.106946_bib0041","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1159\/000077807","article-title":"Addition of teicoplanin or vancomycin for the treatment of documented bacteremia due to Gram-positive cocci in neutropenic patients with hematological malignancies: microbiological, clinical and economic evaluation","volume":"50","author":"D\u2019Antonio","year":"2004","journal-title":"Chemotherapy"},{"key":"10.1016\/j.ijantimicag.2023.106946_bib0042","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1186\/1471-2334-14-289","article-title":"A randomized phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: the ASSURE study","volume":"14","author":"Stryjewski","year":"2014","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106946_bib0043","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1186\/s13063-018-2702-8","article-title":"A randomized phase 2B trial of vancomycin versus daptomycin for the treatment of methicillin-resistant Staphylococcus aureus bacteremia due to isolates with high vancomycin minimum inhibitory concentrations: results of a prematurely terminated study","volume":"19","author":"Kalimuddin","year":"2018","journal-title":"Trials"},{"key":"10.1016\/j.ijantimicag.2023.106946_bib0044","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.cmi.2018.01.010","article-title":"Efficacy and safety of fosfomycin plus imipenem versus vancomycin for complicated bacteraemia and endocarditis due to methicillin-resistant Staphylococcus aureus: a randomized clinical trial","volume":"24","author":"Peric\u00e0s","year":"2018","journal-title":"Clinical Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2023.106946_bib0045","first-page":"63","article-title":"Clinical data on daptomycin plus ceftaroline versus standard of care monotherapy in the treatment of methicillin-resistant Staphylococcus aureus bacteremia","author":"Geriak","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106946_bib0046","doi-asserted-by":"crossref","first-page":"80","DOI":"10.2165\/00044011-199612020-00003","article-title":"Comparative study of teicoplanin vs vancomycin for the treatment of methicillin-resistant Staphylococcus aureus bacteraemia","volume":"12","author":"Liu","year":"1996","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.ijantimicag.2023.106946_bib0047","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa053783","article-title":"Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus","volume":"355","author":"Fowler","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2023.106946_bib0048","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1128\/AAC.00700-07","article-title":"Outcome of vancomycin treatment in patients with methicillin-susceptible Staphylococcus aureus bacteremia","volume":"52","author":"Kim","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106946_bib0049","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1093\/cid\/cir764","article-title":"Daptomycin versus vancomycin for bloodstream infections due to methicillin-resistant Staphylococcus aureus with a high vancomycin minimum inhibitory concentration: a case-control study","volume":"54","author":"Moore","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106946_bib0050","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1093\/cid\/cit112","article-title":"Early use of daptomycin versus vancomycin for methicillin-resistant Staphylococcus aureus bacteremia with vancomycin minimum inhibitory concentration >1 mg\/L: a matched cohort study","volume":"56","author":"Murray","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106946_bib0051","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1093\/cid\/ciu165","article-title":"Snydman DR The efficacy of daptomycin versus vancomycin for methicillin-resistant Staphylococcus aureus bloodstream infection in patients with impaired renal function","volume":"58","author":"Weston","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106946_bib0052","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/MAJ.0000000000000338","article-title":"Self TH Evaluation of the treatment of methicillin-resistant Staphylococcus aureus bacteremia","volume":"349","author":"Usery","year":"2015","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.ijantimicag.2023.106946_bib0053","doi-asserted-by":"crossref","first-page":"5841","DOI":"10.1128\/AAC.00227-16","article-title":"Daptomycin improves outcomes regardless of vancomycin MIC in a propensity-matched analysis of methicillin-resistant Staphylococcus aureus bloodstream infections","volume":"60","author":"Claeys","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106946_bib0054","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.clinthera.2015.09.017","article-title":"Comparative effectiveness of vancomycin versus daptomycin for MRSA bacteremia with vancomycin MIC >1 mg\/L: a multicenter evaluation","volume":"38","author":"Moise","year":"2016","journal-title":"Clin Therapeut"},{"key":"10.1016\/j.ijantimicag.2023.106946_bib0055","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ijid.2017.01.019","article-title":"Ceftaroline fosamil monotherapy for methicillin-resistant Staphylococcus aureus bacteremia: a comparative clinical outcomes study","volume":"57","author":"Arshad","year":"2017","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106946_bib0056","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s40121-021-00401-1","article-title":"Claeys KC Using an ordinal approach to compare outcomes between vancomycin versus ceftaroline or daptomycin in MRSA bloodstream infection","volume":"10","author":"Barlow","year":"2021","journal-title":"Infect Dis Ther"},{"issue":"Suppl 1","key":"10.1016\/j.ijantimicag.2023.106946_bib0057","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.1093\/cid\/ciaa1572","article-title":"Comparative effectiveness of switching to daptomycin versus remaining on vancomycin among patients with methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections","volume":"72","author":"Schweizer","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106946_bib0058","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.ijantimicag.2012.10.019","article-title":"Influence of early daptomycin therapy on treatment outcome of meticillin-resistant Staphylococcus aureus bacteraemia with high vancomycin minimum inhibitory concentrations","volume":"41","author":"Cheng","year":"2013","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2023.106946_bib0059","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41579-018-0147-4","article-title":"Methicillin-resistant Staphylococcus aureus: an overview of basic and clinical research","volume":"17","author":"Turner","year":"2019","journal-title":"Nature Rev Microbiol"},{"key":"10.1016\/j.ijantimicag.2023.106946_bib0060","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1093\/cid\/ciz257","article-title":"Defining the breakpoint duration of Staphylococcus aureus bacteremia predictive of poor outcomes","volume":"70","author":"Minejima","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106946_bib0061","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1128\/AAC.00939-06","article-title":"Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia","volume":"51","author":"Moise","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106946_bib0062","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1128\/JCM.42.6.2398-2402.2004","article-title":"Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia","volume":"42","author":"Sakoulas","year":"2004","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijantimicag.2023.106946_bib0063","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s10156-010-0086-0","article-title":"Clinical characteristics of vancomycin minimum inhibitory concentration of 2 \u03bcg\/mL methicillin-resistant Staphylococcus aureus strains isolated from patients with bacteremia","volume":"17","author":"Takesue","year":"2011","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106946_bib0064","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1093\/cid\/cir935","article-title":"The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis","volume":"54","author":"van Hal","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106946_bib0065","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1093\/jac\/dkq050","article-title":"Predictors of persistent methicillin-resistant Staphylococcus aureus bacteraemia in patients treated with vancomycin","volume":"65","author":"Yoon","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106946_bib0066","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1177\/1060028021991943","article-title":"High-dose daptomycin and clinical applications","volume":"55","author":"Jones","year":"2021","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ijantimicag.2023.106946_bib0067","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/nrmicro.2017.99","article-title":"Hall-Stoodley L Targeting microbial biofilms: current and prospective therapeutic strategies","volume":"15","author":"Koo","year":"2017","journal-title":"Nature Rev Microbiol"},{"key":"10.1016\/j.ijantimicag.2023.106946_bib0068","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1469-0691.2006.01625.x","article-title":"Test results: characterising the antimicrobial activity of daptomycin","volume":"12","author":"Wiedemann","year":"2006","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2023.106946_bib0069","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02074-19","article-title":"Impact of daptomycin dose exposure alone or in combination with \u03b2-lactams or rifampin against vancomycin-resistant enterococci in an in vitro biofilm model","volume":"64","author":"Jahanbakhsh","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106946_bib0070","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1128\/AAC.44.4.1062-1066.2000","article-title":"In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against Staphylococci and Enterococci, including vancomycin- intermediate and -resistant strains","volume":"44","author":"Rybak","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106946_bib0071","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jac\/dkx349","volume":"73","author":"Heidary","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106946_bib0072","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1097\/CCM.0b013e3181eb3b96","article-title":"Linezolid versus vancomycin or teicoplanin for nosocomial pneumonia: a systematic review and meta-analysis","volume":"38","author":"Kalil","year":"2010","journal-title":"Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2023.106946_bib0073","first-page":"694","article-title":"The use of vancomycin with its therapeutic and adverse effects: a review","volume":"19","author":"Bruniera","year":"2015","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.ijantimicag.2023.106946_bib0074","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1093\/toxsci\/kfn203","article-title":"Gene expression analysis reveals new possible mechanisms of vancomycin-induced nephrotoxicity and identifies gene markers candidates","volume":"107","author":"Dieterich","year":"2009","journal-title":"Toxicol Sci"},{"key":"10.1016\/j.ijantimicag.2023.106946_bib0075","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1093\/cid\/ciaa303","volume":"71","author":"Rybak","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106946_bib0076","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1093\/cid\/cir124","article-title":"Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets","volume":"52","author":"Kullar","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106946_bib0077","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0077169","article-title":"Benefits of therapeutic drug monitoring of vancomycin: a systematic review and meta-analysis","volume":"8","author":"Ye","year":"2013","journal-title":"PLoS One"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092485792300225X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092485792300225X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:46:23Z","timestamp":1760377583000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092485792300225X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":77,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S092485792300225X"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.106946","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of vancomycin for the treatment of Staphylococcus aureus bacteraemia: a systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.106946","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106946"}}